Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
Bivalent and monovalent BA.1‒adapted vaccines had a safety profile similar to original BNT162b2 30 μg and induced substantial neutralizing responses against Omicron BA.1 and ancestral strains.NCT04955626.
Authors
- Xuping Xie
- Juleen Gayed (ORCID: https://orcid.org/0009-0004-2974-5302)
- Nicholas Kitchin (ORCID: https://orcid.org/0000-0002-1808-3380)
- Vishva Bangad
- Kenneth Koury
- Michael K. Dever
- Stephen Lockhart (ORCID: https://orcid.org/0000-0002-0805-2193)
- W. C. Gruber
- Oyeniyi Diya
- Federico Mensa (ORCID: https://orcid.org/0000-0002-9421-1268)
- Ingrid L. Scully (ORCID: https://orcid.org/0000-0001-8249-0397)
- John Ginis
- Lisa S. Usdan (ORCID: https://orcid.org/0000-0002-5788-3938)
- Claire Lu
- Patricia Winokur
- Jing Zou
- David Cooper
- Uğur Şahin
- Xia Xu
- David Fitz-Patrick
- L Tyler Wadsworth
- Kena A Swanson
- Jose F Cardona
- Sandra Buitrago
- Kevin Cannon
- Ӧzlem Türeci
- Ying Zhang
- Kathrin U Jansen
Institutions
- University of Iowa (US)
- University of North Carolina Wilmington (US)
- Pfizer (United States) (US)
- International Research Associates (United States) (US)
- Orlando Clinical Research Center (US)
- East–West Center (US)
- CNS Healthcare (US)
- BioNTech (Germany) (DE)
- Sundance Clinical Research (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1093/cid/ciag026
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00